维普中文期刊产品整合服务
19篇 您的检索式:作者名="Scelfo"
    题名 作者 年代 出处 被引量
1Gain of imprinting at chromosome 11p15:a pathogenetic mechanism identified in human hepatocarcinomas显示文摘Schwienbacher C Gramantieri L Scelfo R 0,,:1
2Involvement of cerebellum in emo- tional behavior 显示文摘Strata P Scelfo B Sacchetti B 2011Physiol Res2011,601,:1
3A mathematical model of the locomotor apparatue 显示文摘Caldrale PM Scelfo G 1987Engineering in Medicine1987,16,:1
4Abnormal RNA expression of 11p15 imprinted genes and kidney developmental genes in Wilms'tumor显示文摘Schwienbacher C Angioni A Scelfo R 2000Cancer Res2000,60,6:1
5Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas 显示文摘Schwienhacher C Gramantieri L Scelfo R 2000Proc Natl Acad Sci USA2000,97,10:1
6Abnormal RNA expression of 11p15 imprinted genes and kidney developmental genes in Wilms' tumor显示文摘Schwienbacher C Angioni A Scelfo R 2000Cancer Res2000,60,6:1
7Trace metal distributions off the Antarctic Peninsula in the Weddell Sea 显示文摘SAIUDO-WILHELMY S A OLSEN K A SCELFO J M 2002Marine Chemistry2002,77,23:1
8Cerebellum and emotional behavior显示文摘Sacchetti B Scelfo B Strata P 2009Neuroscience2009,162,:1
9Learing-related long-term potenti- ation of inhibitory synapses in cerebellar cortex 显示文摘Scelfo B Sacchetti B Strata P 2008Proc Natl Acad Sci USA2008,105,2:1
10Tet proteins connect the O-linked N-acetylglucosamine transferase Ogt to chromatin in embryonic stem cells显示文摘Vella P Scelfo A Jammula S 2013Mol Cell2013,49,4:1
11Gain of imprinting at chromosome 11p15:a pathogenetic mechanism identified in human hepatocarcinomas显示文摘Schwienbacher C Gramantieri L Scelfo R 2000Proc Natl Acad Sci USA2000,97,10:1
12Tet proteins connect the O-linked N-acetylglucosamine transferase OGT to chromatin in embryonic stem cells显示文摘Vella P Scelfo A Jammula S 2013Mol Cell2013,49,4:1
13Leafing - related long - term potentiation of Inhibitory synapses in cerebellar cortex 显示文摘Scelfo B Sacchetti B Strata P 2008Proc Natl Acad Sci USA2008,105,2:1
14Gain of im- printing at chromosome 11p15A pathogenetic meehanism i dentified in human hepatocareinomas 显示文摘Schwienbacher C Gramantieri L Scelfo R 2000Proc Natl Acad Sci U S A2000,97,10:1
15Long-term Bioaccumulation Monitoring with Transplanted Bivalves in the San Francisco Estuary显示文摘Andrew J. Gunther Jay A. Davis Dane D. Hardin Jordan Gold David Bell Jonathan R. Crick Genine M. Scelfo Jose Sericano Mark Stephenson 1999Marine Pollution Bulletin1999,,3:1
16Lead in calcium supplements显示文摘Scelfo GM Flegal AR 2000Environ Health Perspect2000,108,4:1
17Gain of imprinting at chromosome 11p15: a pathogenetic mechanism identified in human hepatocarcinoma显示文摘Schwienbacher C Gramantieri L Scelfo R 2000Proc Natl Acad Sci USA2000,97,10:1
18Polycomb-dependent H3- K27mel and H3K27me2 regulate active transcription and en- hancer fidelity 显示文摘Ferrari K J Scelfo A Jammula S 2014Mol cell2014,53,1:1
19An international survey of classification and treatment choices for group D retinoblastoma显示文摘AIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region.METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism.RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Children's Hospital of Los Angeles(CHLA) version, 33% used the Children's Oncology Group(COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center(P<0.0001). CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.Christina Scelfo Jasmine H Francis Vikas Khetan Thomas Jenkins Brian Marr David H Abramson Carol L Shields Jacob Pe’er Francis Munier Jesse Berry J.William Harbour Andrey Yarovoy Evandro Lucena Timothy G Murray Pooja Bhagia Evelyn Paysse Samuray Tuncer Guillermo L Chantada Annette C Moll Tatiana Ushakova David A Plager Islamov Ziyovuddin Carlos A Leal Miguel A Materin Xun-Da Ji Jose W Cursino Rodrigo Polania Hayyam Kiratli Charlotta All-Ericsson Rejin Kebudi Santosh G Honavar Vicktoria Vishnevskia-Dai Sidnel Epelman Anthony B Daniels Jeanie D Ling Fousseyni Traore Marco A Ramirez-Ortiz 2017International Journal of Ophthalmology(English edition)2017,10,6:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费